Alpha-synuclein, inflammation, nerve health markers lowered with risvodetinib
Written by Patricia Inácio, PhD | Aug. 7, 2026
- Risvodetinib is an oral experimental therapy being developed to treat Parkinson’s disease and address underlying cellular damage.
- A 12-week Phase 2 trial showed the oral therapy significantly reduced multiple disease-related biomarkers in patients.
- The markers reflected processes associated with nerve cell degeneration, mitochondrial health, and neuroinflammation.
Risvodetinib, an oral therapy Abli Therapeutics is developing for people with Parkinson’s disease, reduced multiple disease-related biomarkers, the company announced.
The findings come from an expanded analysis of the 201 Phase 2 study (NCT05424276), which enrolled patients with bradykinesia (slowed movement), a hallmark symptom of Parkinson’s.
The trial tested once-daily risvodetinib against a placebo for three months in people with early, untreated Parkinson’s. Earlier results suggested that risvodetinib stabilized disease status and severity, and improved patient quality of life.
The new biomarker analysis involved 7,300 individual measures from as many as 80 participants in the 201 study. It expanded on earlier skin-biopsy findings by adding longitudinal blood measures from 80 participants and cerebrospinal fluid (CSF, the fluid surrounding the brain and spinal cord) measures from six participants, with samples collected at the start and end of the trial.
Eleven disease-related biomarkers measured in tissue, blood, and CSF responded to risvodetinib, according to a company press release, The analysis “has revealed surprising information, both about the underlying processes of disease and how patients respond to risvodetinib treatment,” said Milton Werner, Abli’s chairman and CEO.
Recent Comments